January 11, 2021 The CARBALIVE Consortium announces positive results of a Phase 2 equivalent trial of engineered macroporous carbons as a novel treatment for cirrhosis The CARBALIVE Consortium is focused on developing a novel treatment for patients with advanced liver disease. It is composed of partners from across Europe, led by University College London, and includes Yaqrit, a life sciences company and the intellectual property owner of Carbalive™ and the European Foundation for the Study of Chronic Liver Failure, among others.

The CARBALIVE Consortium has announced that the Phase 2 clinical trial has obtained positive data on efficacy of Carbalive™, a product candidate for the treatment of patients with decompensated cirrhosis.

The Consortium is developing and testing Carbalive™, an orally-administered, non-absorbable engineered carbon of controlled porosity. Carbalive™ is specifically designed to remove harmful bacterial toxins from the gut, reduce gut inflammation and its permeability, preventing them from leaking into the rest of the body. This academic-industrial consortium has received funding for the project from the European Union's Horizon 2020 research and innovation programme under grant agreement No 634579

Download attached document (745,56 KB)